Duloxetine Medical Valley 60 mg Enterokapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

duloxetine medical valley 60 mg enterokapsel, hård

medical valley invest ab - duloxetinhydroklorid - enterokapsel, hård - 60 mg - propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; sackaros hjälpämne; sockersfärer hjälpämne; duloxetinhydroklorid 67,22 mg aktiv substans; natriumlaurilsulfat hjälpämne

Duloxetine Medical Valley 30 mg Enterokapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

duloxetine medical valley 30 mg enterokapsel, hård

medical valley invest ab - duloxetinhydroklorid - enterokapsel, hård - 30 mg - duloxetinhydroklorid 33,61 mg aktiv substans; sockersfärer hjälpämne; natriumlaurilsulfat hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; sackaros hjälpämne

Dasatinib Accord Europeiska unionen - svenska - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Europeiska unionen - svenska - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Memantine Pharmascope 10 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

memantine pharmascope 10 mg filmdragerad tablett

pharmascope ltd - memantinhydroklorid - filmdragerad tablett - 10 mg - memantinhydroklorid 10 mg aktiv substans - memantin

Memantine Pharmascope 20 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

memantine pharmascope 20 mg filmdragerad tablett

pharmascope ltd - memantinhydroklorid - filmdragerad tablett - 20 mg - memantinhydroklorid 20 mg aktiv substans - memantin

Gabapentin Rivopharm 600 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gabapentin rivopharm 600 mg filmdragerad tablett

rivopharm ltd. - gabapentin - filmdragerad tablett - 600 mg - gabapentin 600 mg aktiv substans - gabapentin

Gabapentin Rivopharm 800 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gabapentin rivopharm 800 mg filmdragerad tablett

rivopharm ltd. - gabapentin - filmdragerad tablett - 800 mg - gabapentin 800 mg aktiv substans - gabapentin

Carboplatin Rivopharm 10 mg/ml Koncentrat till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

carboplatin rivopharm 10 mg/ml koncentrat till infusionsvätska, lösning

rivopharm ltd. - karboplatin - koncentrat till infusionsvätska, lösning - 10 mg/ml - mannitol hjälpämne; karboplatin 10 mg aktiv substans - karboplatin

Pioglitazone Rivopharm 45 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pioglitazone rivopharm 45 mg tablett

rivopharm ltd. - pioglitazonhydroklorid - tablett - 45 mg - mannitol hjälpämne; pioglitazonhydroklorid 49,6 mg aktiv substans